The DOI matches its Crossref record.
Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
Open accessAbstract
OBJECTIVE: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies. METHODS: A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. RESULTS: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. Gabapentin can be effective for the treatment of mixed seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome. CONCLUSIONS: The choice of AED depends upon seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes where more evidence is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Responsive cortical stimulation for the treatment of medically intractable partial epilepsy
Morrell, M. J. (2011) · Neurology · doi:10.1212/wnl.0b013e3182302056 · Cited by 1,282
Guerrini, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68182-8 · Cited by 848
Heck, C. N., King‐Stephens, D., Massey, A. D., Nair, D. R., Jobst, B. C., Barkley, G. L., Salanova, V., Cole, A. J., Smith, M. C., Gwinn, R. P., et al. (2014) · Epilepsia · doi:10.1111/epi.12534 · Cited by 651
Self-citationLong-term treatment with responsive brain stimulation in adults with refractory partial seizures
Bergey, G. K., Morrell, M. J., Mizrahi, E. M., Goldman, A., King-Stephens, D., Nair, D., Srinivasan, S., Jobst, B., Gross, R. E., Shields, D. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001280 · Cited by 634
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
Metadata
- Authors
- French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., Bergen, D., Hirtz, D., Montouris, G. D., Nespeca, M., Gidal, B., Marks, W. J., Turk, W. R., Fischer, J. H., Bourgeois, B., Wilner, A., Faught, R. E., Sachdeo, R. C., Beydoun, A., & Glauser, T. A.
- Venue
- Neurology
- Published
- 2004-04-27
- Volume
- 62
- Issue
- 8
- Pages
- 1261-1273
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4243636870
- Cited by
- 407
- References
- 0
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. https://app.cochat.ai/papers/10.1212/01.wnl.0000123695.22623.32
- The paper
- French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., Bergen, D., Hirtz, D., Montouris, G. D., Nespeca, M., Gidal, B., Marks, W. J., Turk, W. R., Fischer, J. H., Bourgeois, B., . . . Glauser, T. A. (2004). Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. https://doi.org/10.1212/01.wnl.0000123695.22623.32
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.